From the Department of Clinical Laboratory Immunology and Allergy, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.
Immunology Research Institute of New England, Gardner, Massachusetts.
Allergy Asthma Proc. 2021 Jan 1;42(1):36-42. doi: 10.2500/aap.2021.42.200109.
The latest evidence on the mechanisms, efficacy, and safety of sublingual immunotherapy (SLIT) was reviewed. Interleukin (IL) 35 and IL-35-producing regulatory T cells were assessed as new biomarkers for SLIT responsiveness. A detailed analysis of clinical studies, including timothy grass pollen, 5-grass pollen, ragweed, and house-dust mite SLIT tablets, was provided, including a comparative analysis of efficacy and safety of SLIT versus subcutaneous immunotherapy.
本文回顾了舌下免疫疗法（SLIT）的作用机制、疗效和安全性的最新证据。评估了白细胞介素（IL）35 和产生 IL-35 的调节性 T 细胞作为 SLIT 反应性的新生物标志物。详细分析了临床研究，包括豚草花粉、五花粉、蒿属花粉和屋尘螨 SLIT 片剂，包括 SLIT 与皮下免疫疗法的疗效和安全性的比较分析。
